imatinib mesylate has been researched along with Fever in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chien, HD; Kesely, KR; Low, PS; Noomuna, P; Pantaleo, A; Putt, KS; Tuan, TA; Turrini, FM | 1 |
| Brümmendorf, TH; Cortes, JE; Dmoszynska, A; Duvillié, L; Gambacorti-Passerini, C; Gogat Marchant, K; Kantarjian, HM; Khattry, N; Lipton, JH; Pavlov, D; Rossiev, V; Wong, RS | 1 |
| Bardy-Bouxin, N; Brümmendorf, TH; Cortes, JE; Gambacorti-Passerini, C; Kantarjian, HM; Khoury, HJ; Kim, DW; Leip, E; Matczak, E; Shapiro, M; Turkina, AG; Turnbull, K | 1 |
| Abdulkadyrov, K; Ayala, M; Babu, KG; Bendit, I; Bullorsky, E; Cortes, JE; de Oliveira, JSR; De Souza, CA; Fellague-Chebra, R; Huang, X; Khanna, S; le Coutre, PD; Liang, Z; Lopez, JL; Owugah, T; Sacha, T; Shah, S; Shen, ZX; Szczudlo, T | 1 |
| Dahl, TG; Ghanima, W; Kahrs, J; Tjonnfjord, GE | 1 |
4 trial(s) available for imatinib mesylate and Fever
| Article | Year |
|---|---|
Imatinib augments standard malaria combination therapy without added toxicity.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Fever; Humans; Imatinib Mesylate; Malaria, Falciparum; Middle Aged; Quinolines; Treatment Outcome; Vietnam; Young Adult | 2021 |
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Alanine Transaminase; Aniline Compounds; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Diarrhea; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Myalgia; Nitriles; Pain; Piperazines; Pyrimidines; Quinolines; Vomiting | 2014 |
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Benzamides; Blast Crisis; Diarrhea; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nitriles; Piperazines; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Survival Analysis; Treatment Outcome | 2015 |
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Asia; Biomarkers, Pharmacological; Bone Marrow; Comparative Effectiveness Research; Cytogenetic Analysis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Europe; Exanthema; Female; Fever; Follow-Up Studies; Headache; Hematologic Diseases; Humans; Imatinib Mesylate; Latin America; Leukemia, Myeloid, Chronic-Phase; Male; Metabolic Diseases; Middle Aged; Philadelphia Chromosome; Pyrimidines; Random Allocation; Treatment Failure | 2016 |
1 other study(ies) available for imatinib mesylate and Fever
| Article | Year |
|---|---|
Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
Topics: Benzamides; Cytogenetic Analysis; Disease-Free Survival; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy | 2004 |